Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Hanmi Science Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jong-Hoon Lim

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	Veri yok

Son yönetim güncellemeleri

Recent updates

Hanmi Science Co., Ltd.'s (KRX:008930) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Jan 31

We Think Hanmi Science (KRX:008930) Can Stay On Top Of Its Debt

Jan 05

Shareholders Are Thrilled That The Hanmi Science (KRX:008930) Share Price Increased 100%

Dec 06

CEO

Jong-Hoon Lim (63 yo)

less than a year

Görev süresi

Mr. Jong-Hoon Lim is Chief Executive Officer of Hanmi Science Co., Ltd. from May 2024. He is CSR Executive Director at Hanmi Pharm.Co., Ltd. He served as Managing Director of Hanmi Pharmaceutical Co. Ltd...

Hanmi Science Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Less than half of directors are independent

Hanmi Science Co., Ltd., Annual General Meeting, Mar 26, 2021

Recent updates

Returns On Capital Are Showing Encouraging Signs At Hanmi Science (KRX:008930)

Now 23% overvalued after recent price rise

Here's Why Hanmi Science (KRX:008930) Can Manage Its Debt Responsibly

Investor sentiment deteriorates as stock falls 19%

Hanmi Science Co., Ltd. to Report Q2, 2024 Results on Jul 30, 2024

Hanmi Science Co., Ltd. (KRX:008930) Not Flying Under The Radar

Hanmi Science Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

OCI Holdings Company Ltd. (KOSE:A010060) cancelled the acquisition of 10.94% stake in Hanmi Science Co., Ltd. (KOSE:A008930) from Song Young Sook, Kim Won Se and Kim JI Woo.

Now 24% overvalued after recent price rise

Now 25% overvalued after recent price rise

Hanmi Science Co., Ltd. to Report Fiscal Year 2023 Results on Feb 02, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 45%

Upcoming dividend of ₩196 per share at 0.5% yield

Hanmi Science Co., Ltd. to Report Q3, 2023 Results on Nov 01, 2023

Hanmi Science Co., Ltd. Announces Successful Launch of JVM's Automated Drug Dispensing System via High-End Robot Arm 'MENITH' in the European Market

Hanmi Science Co., Ltd. Announces Successful Launch of JVM's Automated Drug Dispensing System via High-End Robot Arm 'MENITH' in the European Market

New minor risk - Share price stability

Investor sentiment improves as stock rises 24%

Hanmi Science Co., Ltd. to Report Q2, 2023 Results on Jul 28, 2023

Full year 2022 earnings released: EPS: ₩1,010 (vs ₩626 in FY 2021)

Investor sentiment improves as stock rises 20%

Upcoming dividend of ₩196 per share

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Upcoming dividend of ₩196 per share

Is Hanmi Science (KRX:008930) Using Too Much Debt?

Hanmi Science Co., Ltd., Annual General Meeting, Mar 26, 2021

New 90-day low: ₩61,100

Hanmi Science Co., Ltd.'s (KRX:008930) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

New 90-day high: ₩90,500

We Think Hanmi Science (KRX:008930) Can Stay On Top Of Its Debt

Shareholders Are Thrilled That The Hanmi Science (KRX:008930) Share Price Increased 100%

New 90-day high: ₩65,700

New 90-day high - ₩46,200

CEO

Görev süresi